FOXP3 Polymorphism and Susceptibility to Pediatric Acute Lymphocytic Leukemia (ALL): A Preliminary Data

Authors

  • Eman A. El-maadawy Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI], University of Sadat City,Sadat City,32958, Egypt.
  • Rania M. Bakry SouthEgypt Cancer Institute, AssiutUniversity,Assiut,, 71511, Egypt.
  • Mohamed M. Moussa Clinical Hematology and Bone Marrow Transplantation, Ain-Shams University, Cairo, 11865,Egypt
  • Sobhy Hasab El-Naby Zoology Department, Faculty of Science, Menoufiya University, Shebin el kom,, 32511, Egypt
  • Roba M. Talaat Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI], University of Sadat City,Sadat City,32958, Egypt.

Keywords:

FOXP3, SNP, pediatric ALL, RFLP

Abstract

FOXP3 (forkhead box P3) polymorphism is associated with many inflammatory diseases and cancers. Acute lymphoblastic leukemia (ALL) is the most common type of pediatric malignancies.This study was designed to investigate the impact of FOXP3 (-3279C/A and -2383C/T) gene polymorphism on the susceptibility of Egyptian children to ALL. A total of 128 subjects with ALL and 124 healthy controls were enrolled in this study. Genotyping of FOXP3 (-3279C/A and -2383C/T) were performed by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). There was a significant increase (P<0.01) in FOXP3 (-3279CC) genotype, while FOXP3 -3279CA genotype was significantly decreased in ALL patients compared to controls. Insignificant change in FOXP3 (-2383C/T) genotypes was demonstrated between both groups. FOXP3 (-2383CC) genotype was significantly decreased (p<0.05) in treatment responders compared to non-responders and a significant increased (p<0.05) in relapsed patients comparing to the non-relapsed group. Taken together, our pilot study pointed to the potential role of FOXP3 (-3279C/A) gene polymorphisms in Egyptian children ALL susceptibility. An additional prospective large scale study should be carried out to support our findings.

References

. S.C.Bernard, E.H. Abdelsamad, P.A. Johnson, D.L. Chapman, andM.Parvathanen, “Pediatric Leukemia: Diagnosis to Treatment–A Review,”J Cancer Clin Trials, vol. 2, pp.30, 2017.

. M.A. Smith, S.F.Altekruse, P.C. Adamson, G.H.Reaman, andN.L. Seibel, “Declining childhood and adolescent cancer mortality,”Cancer, vol. 120, pp.2497-506, 2014.

. P.Bhatia, S.Masih, N.Varma, D.Bansal, andA.Trehan, “High Expression of Lung Resistance Protein mRNA at Diagnosis Predicts Poor Early Response to Induction Chemotherapy in Childhood Acute Lymphoblastic Leukemia,”Asian Pac J Cancer Prev, vol. 16, pp.6663-8, 2015.

. A.Miranda-Filho, M.Piñeros, J.Ferlay, I.Soerjomataram, A.Monnereau, andF.Bray, “Epidemiological patterns of leukaemia in 184 countries: a population-based study,”LancetHaematol, vol. 5, pp.e14-e24,2018.

. S.Sakaguchi, “Regulatory T cells: key controllers of immunologic self-tolerance,”Cell, vol. 101, pp.455-8, 2000.

. A.Huynh, M.DuPage, B.Priyadharshini, P.T.Sage, J.Quiros, C.M.Borges, N.et al., “Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability,”NatImmunol, vol. 16, pp.188-96,2015.

. Y. Tang, X.Xu, S.Guo, C. Zhang , Y. Tang , Y.Tian , et al., “An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma,”.PLoS ONE, vol. 9, pp. e91551, 2014.

. J. Shou,Z.Zhang,Y. Lai, Z. Chen,andJ.Huang, “Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+Tregs: a systematic review and metaanalysis,”BMC Cancer, vol. 16, pp. 687, 2016.

. C.A.LindqvistandA.S.Loskog, “T regulatory cells in B-cell malignancy – tumour support or kiss of death?,”Immunology, vol.135, pp.255-60, 2012.

. J.D.Fontenot, M.A.Gavin,andA.Y.Rudensky, “FOXP3 programs the development and function of CD4+CD25+regulatory T cells,”NatImmunol, vol. 4, pp.330-6, 2003.

. Y.Feng, A.Arvey, T.Chinen, J.van der Veeken, G.Gasteiger, andA.Y.Rudensky.“Control of the inheritance of regulatory T cell identity by a cis element in the FOXP3 locus,”Cell, vol. 158, pp.749-63, 2014.

. M.E.Brunkow, E.W.Jeffery, K.A.Hjerrild, B.Paeper, L.B.Clark, S.A.Yasayko, et al., “Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse,”Nat. Nat Genet, vol. 27, pp.68-73, 2001.

. Z.Cheng, Y.Guo,andL.Ming, “Functional FOXP3 polymorphisms and the susceptibility to cancer: An update meta-analysis,”Medicine (Baltimore), vol. 97, pp.e11927, 2018.

. W. M.Bassuny, K.Ihara, Y.Sasaki, R.Kuromaru, H.Kohno, N.Matsuura ,et al., “A functional polymorphism in the promoter/enhancer region of the FOXP3/Scurfin gene associated with type 1 diabetes,”Immunogenetics, vol. 55, pp.149- 56, 2003.

. R.M.Talaat, S.M.Seada, G.I.Mohamed, A.T.Abdel-Moez,andM.Mokhles, “Polymorphism of FOXP3 in Egyptian Patients with Hepatocellular Carcinoma (HCC),”EC Gastroenterology and Digestive System, vol. 5.2, pp.97-106, 2018.

. M.Smith, D.Arthur, B.Camitta, A.J.Carroll, W.Crist, P.Gaynon,et al.,“Uniformapproach to risk classification and treatment assignment forchildren with acutelymphoblasticleukemia,”JClinOncol, vol. 14, pp.18-24, 1996.

. S.Kishi, W.Yang, B.Boureau, S.Morand, S.Das, P.Chen, E.H.et al., “Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acutelymphoblasticleukemia,”Blood, vol. 103, pp.67-72, 2004.

. N.Inoue, M.Watanabe, M.Morita, R.Tomizawa, T.Akamizu, K.Tatsumi, et al., “Association of functional polymorphisms related to the transcriptional level of FOXP3 with prognosis of autoimmune thyroid disease,”ClinExpImmunol, vol.162, pp.402-6, 2010.

. L.L.JiangandL.W.Ruan, “Association between FOXP3 promoter polymorphisms and cancer risk: A meta-analysis. OncolLett, vol. 8, pp.2795-99,2014.

. G.Roncador, J.F.Garcia, J.F Garcia, L.Maestre, E.Lucas, J.Menarguez, et al., “FOXP3, a selective marker for a subset of adult T-cell leukemia/lymphoma,”Leukemia, vol. 19,pp.2247-53.2005.

. Z.Piao, H.J.Kim, J.Y.Choi, C.R.Hong, J.W.Lee, H.J.Kang, et al., “Effect of FOXP3 polymorphism on the clinical outcomes after allogeneic hematopoietic stem cell transplantation in pediatric acute leukemia patients,”IntImmunopharmacol, vol. 31, pp.132-9, 2016.

. N. Chatrabnous, A. Ghaderi, A. Ariafar, M.S. Razeghinia, M. Nematiand A. Jafarzadeh, “ Serum concentration of interleukin-35 and its association with tumor stages and FOXP3 gene polymorphism in patients with prostate cancer,”Cytokine, vol. 113, pp. 221-7 , 2019.

. Y. Chen, X. Qi, C. Bian, C. Ling, T. Yi, X. Mu, et al., “ The association of FOXP3 gene polymorphisms with cancer susceptibility: a comprehensive systemic review and meta-analysis,”Biosci Rep, vol. 39, pp.BSR20181809, 2019.

. F. Cezar-Dos-Santos, R.S. Ferreira, N.C.M.Okuyama, K.P. Trugilo, M.M. Sena, É.R. Pereira, et al.,“ FOXP3immunoregulatory gene variants are independent predictors of human papillomavirus infection and cervical cancer precursor lesions,”J Cancer Res ClinOncol, vol. 145, pp. 2013-25,2019

. T. Flauzino, D.F. Alfieri, W.L. de Carvalho Jennings Pereira, S.R. Oliveira, A.P. Kallaur, M.A.B. Lozovoy, et al., “ The rs3761548 FOXP3 variant is associated with multiple sclerosis and transforming growth factor β1 levels in female patients,”Inflamm Res, vol. 68, pp.933-43, 2019.

. H. Thude, P. Tiede, M. Sterneck, B. Nashan, M. Koc, “Impact of TBX21, GATA3, and FOXP3 gene polymorphisms on acute cellular rejection after liver transplantation,”HLA, vol. 93, pp. 97-101, 2019.

. S.L. Xia, S.J. Ying, Q.R. Lin, X.Q. Wang, W.J. Hong, Z.J. Lin, et al.,“Association of Ulcerative Colitis with FOXP3 Gene Polymorphisms and Its Colonic Expression in Chinese Patients,” Gastroenterol Res Pract, vol. 2019, pp. 4052168, 2019.

. N. Fathima, P. Narne and M. Ishaq, “Association and gene-gene interaction analyses for polymorphic variants in CTLA-4 and FOXP3 genes: role in susceptibility to autoimmune thyroid disease,”Endocrine, vol. 64, pp.591-604, 2019.

. S. Xia, D. Zhang, S. Zheng, C. Wu, Q. Lin, S. Ying, et al.,“Association of Crohn's disease with Foxp3 gene polymorphisms and its colonic expression in Chinese patients,”JClin Lab Anal, vol. 33, pp. e22835, 2019.

. M.A. Elsohafy, A.A. Elghzaly, H.M. Abdelsalam and M.A. Gaballah,“Assessment of the Possible Role of FOXP3 Gene (rs3761548) Polymorphism in Psoriasis Vulgaris Susceptibility and Pathogenesis: Egyptian Study,”IndianDermatol Online J, vol. 10, pp. 401-5, 2019.

. M.Nam, S.Shin, K.U.Park, I.Kim, S.S.Yoon, T.K.Kwon,et al., “Association of FOXP3 Single Nucleotide Polymorphisms With Clinical Outcomes After Allogenic Hematopoietic Stem Cell Transplantation,”Ann Lab Med,vol. 38,no.6 pp.591– 8, 2018.

. M. Moradi, S. Naeimi, S. Asadzade and A. Rahi,“ Genetic association study of promoter variation rs3761549 in the FOXP3 gene of Iranian patients diagnosed with brain tumour,”J Cell Biochem, vol. 10.1002/jcb.28473, 2019.

. J.M. Oda, B.K. Hirata, R.L. Guembarovski,M.A. Watanabe, “Genetic polymorphism in FOXP3 gene: imbalance in regulatory T-cell role and development of human diseases,”J Genet, vol. 92, pp.163-71, 2013.

Downloads

Published

2020-08-14

How to Cite

El-maadawy, E. A. ., Bakry, R. M. ., Moussa, M. M. ., El-Naby, S. H. ., & Talaat, R. M. . (2020). FOXP3 Polymorphism and Susceptibility to Pediatric Acute Lymphocytic Leukemia (ALL): A Preliminary Data. International Journal of Sciences: Basic and Applied Research (IJSBAR), 53(2), 159–170. Retrieved from https://gssrr.org/index.php/JournalOfBasicAndApplied/article/view/10626

Issue

Section

Articles